Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019652 · ClinicalTrials.gov registry record · Phase 1
The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers
A Phase 1 study of Hypertension and Mineralocorticoid Receptor Antagonist, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT04019652 is a Phase 1 study of Hypertension and Mineralocorticoid Receptor Antagonist that has completed, run by Daiichi Sankyo. The registered enrollment target is 55 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04019652, a Phase 1 study of Hypertension and Mineralocorticoid Receptor Antagonist, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test if a study drug (CS-3150) will affect the heart rate in healthy males and females. Two doses of the study drug will be tested. Heart rate is not expected to be different between the study groups.
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG CS-3150
- DRUG Placebo matching moxifloxacin tablet
- DRUG Placebo matching CS-3150
Study Locations (1)
Texas
- Worldwide Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-11-19 |
| Est. Completion | 2015-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04019652
The ClinicalTrials.gov registry entry for NCT04019652 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT04019652 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04019652 about?
NCT04019652 is a clinical study titled "The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers". This study will test if a study drug (CS-3150) will affect the heart rate in healthy males and females. Two doses of the study drug will be tested. Heart rate is not expected to be different between the study groups.
What is the current status of trial NCT04019652?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2015-11-19. Estimated completion is 2015-12-23.
What conditions does trial NCT04019652 study?
This clinical trial studies the following conditions: Hypertension, Mineralocorticoid Receptor Antagonist.
What interventions are being tested in trial NCT04019652?
The interventions under investigation include: Moxifloxacin (DRUG), CS-3150 (DRUG), Placebo matching moxifloxacin tablet (DRUG), Placebo matching CS-3150 (DRUG).
Who is sponsoring clinical trial NCT04019652?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04019652 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Sympathetic Mechanisms in Obesity-Crossover Design
RECRUITING · Phase 1
-
Targeting Endoplasmic Reticulum Stress in Human Hypertension
RECRUITING · Phase 1
-
: Vascular Function in Health and Disease
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.